Special Issue

Immunonutrition: Biomedical Basis for Disease Management 2.0

Message from the Guest Editor

Knowledge about the impact of immunonutritional agonists on citizens' health can offer a way to reduce the risk of suffering chronic diseases and even offer a therapeutic potential on these. Innate and adaptive immune effectors operate sequentially and in distinct ways during normal development to prevent alterations in tissue metabolic homeostasis as well as to establish steady-state commensalism. Those are key to correct the distinctive stamp in alterations to the homeostasis of nutrients, leading to immunometabolic-based diseases with a strong impact on future morbidity rates and a reduction in the life expectancy of the population (i.e., non-alcoholic fatty liver disease, metabolic syndrome, cancer). There is evidence of the relevance of perinatal nutrition to developmental programming of innate immune effectors, worsening or improving their contribution to the risk of disease development. Identification and development of immunonutritional agonists, as well as definition of their biomedical action based on life sciences, can greatly accelerate our progress toward precision medicine in health promotion.

Guest Editor

Dr. Jose Laparra Llopis
Madrid Institute for Advanced Studies in Food (IMDEA Food), Madrid, Spain

Deadline for manuscript submissions

closed (31 July 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/133056

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).